Yongyong Lu

443 total citations
20 papers, 256 citations indexed

About

Yongyong Lu is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yongyong Lu has authored 20 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yongyong Lu's work include Cancer-related molecular mechanisms research (5 papers), MicroRNA in disease regulation (4 papers) and RNA modifications and cancer (4 papers). Yongyong Lu is often cited by papers focused on Cancer-related molecular mechanisms research (5 papers), MicroRNA in disease regulation (4 papers) and RNA modifications and cancer (4 papers). Yongyong Lu collaborates with scholars based in China, Hong Kong and United States. Yongyong Lu's co-authors include Zhixian Yu, Weiping Huang, Xixi Huang, Feng Wang, Feng Wang, Haishan Huang, Hang Huang, Yeping Li, Qipeng Xie and Honglei Jin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Oncogene and The FASEB Journal.

In The Last Decade

Yongyong Lu

18 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yongyong Lu China 9 189 144 25 25 23 20 256
Zhihui Feng China 8 270 1.4× 122 0.8× 15 0.6× 17 0.7× 20 0.9× 11 327
Nikunj Maniyar India 6 85 0.4× 47 0.3× 35 1.4× 56 2.2× 32 1.4× 21 264
Vijayalakshmi Ramshankar India 7 81 0.4× 55 0.4× 25 1.0× 45 1.8× 27 1.2× 13 243
Tivoli Nguyen United States 7 132 0.7× 72 0.5× 12 0.5× 17 0.7× 17 0.7× 11 235
A. Hakam United States 6 113 0.6× 28 0.2× 31 1.2× 44 1.8× 82 3.6× 17 247
Marisa Gallant United States 3 93 0.5× 22 0.2× 16 0.6× 43 1.7× 14 0.6× 3 153
Ana Álvarez-Castro Spain 7 134 0.7× 139 1.0× 45 1.8× 109 4.4× 92 4.0× 19 322
А. К. Носов Russia 6 169 0.9× 125 0.9× 59 2.4× 23 0.9× 37 1.6× 55 253
J. Castillo United States 3 130 0.7× 131 0.9× 28 1.1× 39 1.6× 12 0.5× 6 187
Jeffrey Zhao United States 9 49 0.3× 26 0.2× 28 1.1× 77 3.1× 10 0.4× 23 211

Countries citing papers authored by Yongyong Lu

Since Specialization
Citations

This map shows the geographic impact of Yongyong Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongyong Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongyong Lu more than expected).

Fields of papers citing papers by Yongyong Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongyong Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongyong Lu. The network helps show where Yongyong Lu may publish in the future.

Co-authorship network of co-authors of Yongyong Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Yongyong Lu. A scholar is included among the top collaborators of Yongyong Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongyong Lu. Yongyong Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Ning, Peipei Zhang, Yi-Xin Chang, et al.. (2025). XIAP promotes metastasis of bladder cancer cells by ubiquitylating YTHDC1. Cell Death and Disease. 16(1). 205–205. 2 indexed citations
2.
Deng, Wenhai, Shuaibin Wang, Yongyong Lu, et al.. (2025). Hyaluronic acid-modified doxorubicin-covalent organic framework nanoparticles triggered pyroptosis in combinations with immune checkpoint blockade for the treatment of breast cancer. International Journal of Biological Macromolecules. 310(Pt 3). 143265–143265. 2 indexed citations
3.
4.
Lu, Xufeng, Wenhai Deng, Shuaibin Wang, et al.. (2024). PEGylated Elesclomol@Cu(Ⅱ)-based Metal‒organic framework with effective nanozyme performance and cuproptosis induction efficacy for enhanced PD-L1-based immunotherapy. Materials Today Bio. 29. 101317–101317. 13 indexed citations
5.
6.
Zhang, Baodan, Pengcheng Chen, Jie Zhu, & Yongyong Lu. (2024). The quantity, function and anti-tumor effect of Mucosal associated invariant T cells in patients with bladder cancer. International Immunopharmacology. 133. 111892–111892. 2 indexed citations
7.
Lu, Yongyong, et al.. (2023). LncRNA BRCAT54 is downregulated and inhibits cancer cell proliferation by downregulating miR‐130b‐3p through methylation in prostate cancer. Journal of Biochemical and Molecular Toxicology. 38(1). e23552–e23552. 1 indexed citations
8.
Sun, Ning, et al.. (2023). SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription through destabilizing c-Myc protein. Cancer Cell International. 23(1). 48–48. 7 indexed citations
9.
Liao, Hongbing, et al.. (2023). Comprehensive analysis of single-cell RNA-seq and bulk RNA-seq revealed the heterogeneity and convergence of the immune microenvironment in renal cell carcinoma. Functional & Integrative Genomics. 23(2). 193–193. 4 indexed citations
10.
Wang, Yi, Hui Deng, Yihuai Pan, et al.. (2021). Periodontal disease increases the host susceptibility to COVID-19 and its severity: a Mendelian randomization study. Journal of Translational Medicine. 19(1). 528–528. 23 indexed citations
11.
Zhang, Ning, Liping Shen, Yongyong Lu, et al.. (2021). Lnc00892 competes with c-Jun to block NCL transcription, reducing the stability of RhoA/RhoC mRNA and impairing bladder cancer invasion. Oncogene. 40(48). 6579–6589. 14 indexed citations
12.
Huang, Xiu‐Feng, Wenhai Deng, Liangshan Mu, et al.. (2021). Specific Immune Phenotypes Protect Individuals Against COVID-19 Susceptibility and Severity: A Mendelian Randomization Study. SSRN Electronic Journal. 1 indexed citations
13.
14.
Huang, Hang, et al.. (2020). CircRNA_0058063 functions as a ceRNA in bladder cancer progression via targeting miR-486-3p/FOXP4 axis. Bioscience Reports. 40(3). 30 indexed citations
15.
Jin, Honglei, Jiheng Xu, Hongyan Li, et al.. (2020). Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy. Autophagy. 17(4). 840–854. 18 indexed citations
16.
Huang, Weiping, Yongyong Lu, Feng Wang, Xixi Huang, & Zhixian Yu. (2020). <p>Circular RNA circRNA_103809 Accelerates Bladder Cancer Progression and Enhances Chemo-Resistance by Activation of miR-516a-5p/FBXL18 Axis</p>. Cancer Management and Research. Volume 12. 7561–7568. 31 indexed citations
17.
Chang, Yuanyuan, Honglei Jin, Hongyan Li, et al.. (2020). MiRNA‐516a promotes bladder cancer metastasis by inhibiting MMP9 protein degradation via the AKT/FOXO3A/SMURF1 axis. SHILAP Revista de lepidopterología. 10(8). e263–e263. 28 indexed citations
18.
Yan, Huiying, Qi Lin, Yuan Yu, et al.. (2019). Inhibition of UBE2N‐dependent CDK6 protein degradation by miR‐934 promotes human bladder cancer cell growth. The FASEB Journal. 33(11). 12112–12123. 25 indexed citations
19.
Huang, Weiping, Yongyong Lu, Feng Wang, Xixi Huang, & Zhixian Yu. (2018). Downregulation of circular RNA hsa_circ_0000144 inhibits bladder cancer progression via stimulating miR-217 and suppressing RUNX2 expression. Gene. 678. 337–342. 43 indexed citations
20.
Li, Peng, et al.. (2018). Schwannoma of stomach: a clinicopathologic study of 12 cases.. PubMed. 11(3). 1679–1683. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhihui Feng Breakdown of academic impact, for papers by Nikunj Maniyar Breakdown of academic impact, for papers by Vijayalakshmi Ramshankar Breakdown of academic impact, for papers by Tivoli Nguyen Breakdown of academic impact, for papers by A. Hakam Breakdown of academic impact, for papers by Marisa Gallant Breakdown of academic impact, for papers by Ana Álvarez-Castro Breakdown of academic impact, for papers by А. К. Носов Breakdown of academic impact, for papers by J. Castillo Breakdown of academic impact, for papers by Jeffrey Zhao
Rankless by CCL
2026